This AI Startup Just Raised Millions to Spot a Silent Killer

Jan de Vries · 2026-08-21

Here's a story that makes you feel good about where tech is headed. A Stockholm-based MedTech startup called Eyedentity just closed its first oversubscribed funding round. They pulled in $1.4 million to push their AI-powered diagnostic platform for eye diseases into the mainstream. It's not just about the money, though. It's about what that money represents: a serious bet on using artificial intelligence to catch a deadly form of eye cancer earlier than ever before. They're building tech that works with the system we already have, not against it. ### The Funding and the Backers The $1.4 million round was led by Norrsken Launcher, with Karolinska Institutet Innovation and a group of angel investors joining in. That's a pretty solid vote of confidence from a crew that knows what they're looking at. Gustav Stålhammar, the company's co-founder and Chief Scientific Officer, put it simply. "A huge number of images are already taken at opticians," he said. "And there's a trend where opticians are seeing more patients with various vision problems. We can plug right into that existing flow." ### A Wave of European MedTech Investment This isn't happening in a vacuum. Eyedentity's raise is part of a bigger surge of funding into AI-enabled diagnostics across Europe this year. Think about it like this: investors are pouring millions into technologies that help doctors see what the human eye might miss. - ScreenPoint Medical raised $14.6 million for AI-powered breast cancer imaging. - Moonlight AI secured $3 million for advanced image-analysis. - TidalSense brought in $17.8 million for respiratory diagnostics. - neuroClues landed $10.7 million for neurodiagnostics. - ShanX Medtech got a massive $25.7 million financing round. Add in a few others, and you're looking at nearly $75 million flowing into this sector in 2026 alone. It's a clear signal that the market believes in the power of AI to transform early detection. ### The Problem They're Solving Founded just last year, Eyedentity's first target is uveal melanoma. Now, that's a mouthful. In plain English, it's a rare but potentially deadly eye cancer. The tricky part? In its early stages, it can look almost identical to common, harmless eye conditions. That's where their AI comes in. It's designed to analyze fundus images—the kind already snapped during your routine eye exam—and flag the subtle differences that might indicate something serious. Anna Fredrixon from Norrsken Launcher called it "brilliant" because it saves lives without overloading the healthcare system. No new machines, no extra appointments. Just smarter analysis of what's already there. ### The Brains Behind the Operation The founding team is a classic example of cross-disciplinary magic. You've got Gustav Stålhammar, an ocular oncologist and professor, bringing the deep medical expertise. Then there's co-founder and CEO Mats Holmström, a machine learning engineer who previously worked on automating cancer care. They're also backed by the Karolinska Institutet Innovation Incubator, which Holmström says provides more than just advice. "It creates opportunities to meet people who can genuinely make a difference to the company," he noted, highlighting how they first connected with their lead investor through the incubator. The vision is straightforward. By integrating their software into the workflow of opticians, eye clinics, and hospitals, they can screen a much wider population without building a single new clinic. It turns a routine check-up into a potential lifesaver. In a world where healthcare systems are stretched thin, that's the kind of elegant, scalable solution that gets investors—and hopefully, patients—excited.